Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in oncology ...

The Kadmon deal is Sanofi's second pipeline-building acquisition in two months, coming shortly after offering $3.2 billion to take control of its mRNA vaccine partner Translate Bio. Kadmon claimed ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

Sanofi shares rose 0.5% in Paris trading ... with this improved visibility building belief in R&D thereby driving a long-awaited stock re-rating." "We expect quarterly results to continue the ...